-
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for... -
Newly Diagnosed with KRAS-Positive Lung Cancer?
LUNGevity's Amy Moore, PhD, sits down with Mark Awad, MD, PhD, a thoracic oncologist at Dana-Farber Cancer Institute, to discuss KRAS-positive lung cancer and what questions newly... -
Tips for Better Sleep
Sleep tips session with our sleep expert, Peggy Burhenn. -
New Options in Adjuvant Therapy for Early-Stage NSCLC
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the... -
Highlights of the 2022 AACR meeting
The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in... -
KRAS: How It Started vs. How It’s Going
On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer... -
Immunotherapy in Early-Stage Lung Cancer
Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCH), at the 2022 AACR meeting about his findings on immunotherapy in early... -
All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell
On January 31, 2022, Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran...
KRAS